Jubilant Life receives ANDA approval for Amantadine Hydrochloride Tablets

Mumbai, February 10, 2018: Pharma Major,Jubilant Pharma said that its wholly owned subsidiary Jubilant Life Sciences’ material has received Abbreviated New Drug Application (ANDA) final endorsement for Amantadine Hydrochloride Tablets, 100 mg, the generic version of Symmetrel of Endo, Amantadine Hydrochloride Tablets is indicated for the prophylaxis and treatment of symptoms and signs of disease caused by various strains of influenza a virus.

It is also suggested in the therapy of Parkinsonism and drug-induced extrapyramidal reactions. That is the ninth approval that the business has obtained from the USFDA throughout the present financial year.

As on December 31, 2017, Jubilant had a total of 86 ANDAs for Oral Solids filed in the US, where 56 was approved and 12 Injectable filings, of which 10 had been accepted.